|

Tranexamic Acid During Upper GI Endoscopic Resection Procedures

RECRUITINGPhase 4Sponsored by Assaf-Harofeh Medical Center
Actively Recruiting
PhasePhase 4
SponsorAssaf-Harofeh Medical Center
Started2023-02-01
Est. completion2025-02
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05688020

Summary

Endoscopic resection of gastrointestinal lesions may prevent cancer. However, resection is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of upper gastrointestinal lesions.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients referred for endoscopic resection of a non-neoplastic and neoplastic lesions in the upper GI presenting to our tertiary academic center.
* Age \> 18 years

Exclusion Criteria:

* patients with histories of allergic reactions to TXA
* history of seizures
* pregnancy

Conditions5

CancerDuodenal NeoplasmsEsophageal NeoplasmsGastric NeoplasmGastric Polyp

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.